Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
about
Emerging therapeutic targets in esophageal adenocarcinomaAberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinomaThe anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach.Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignanciesGenetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.Epigenetics: principles and practice.Ablation of breast cancer stem cells with radiation.Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxelAbnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: a meta-analysis of cohort studies.Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma.DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclassesReview of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer.Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours.Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerReprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.Epigenetic biomarkers in esophageal cancer.Novel diagnostic and prognostic biomarkers in esophageal cancer.Reprimo, a Potential p53-Dependent Tumor Suppressor Gene, Is Frequently Hypermethylated in Estrogen Receptor α-Positive Breast Cancer.Correlations of Promoter Methylation in WIF-1, RASSF1A, and CDH13 Genes with the Risk and Prognosis of Esophageal Cancer.Emerging molecular targets in esophageal cancersComprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas.Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression.Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma
P2860
Q26751209-E494C6D9-F093-4D72-A621-B445A6D96018Q30506094-7612F02B-4B88-4DA3-95B7-56AFC77A1C37Q33323380-96E1F78A-7BC9-48CE-82F2-68103807EE6FQ33429064-A011DAC0-9448-4BD4-AD0C-8E2412EDF023Q33907989-EFAD16B0-D795-4D05-A245-A7548D4B05ADQ34634735-44AE1D5A-4938-4E67-8E7A-3C0C252BC2E5Q35098483-FAB22254-AB07-4503-A28F-27ED44ABEACCQ35116818-FA86155F-23F9-4058-ACF5-08251372D6CEQ35184495-8F242F6F-6F61-432D-A4A0-4AC87DCC6292Q35205710-D33DF3B0-AB75-484A-97EA-49BD5E1B031EQ35606943-8DC4DAAA-94AF-495F-B6D2-AE6B219E9720Q35667377-1CE98380-C7AB-4B81-AD7D-CC79D9348D76Q35879988-29FCB20B-6243-452E-A5E9-513D41C244E1Q36418030-7883F575-CD65-4DD6-AE90-A1FDD79538C4Q36450457-B4FD82C4-01AF-44A9-85FA-43A83716FEABQ36489832-C3715A20-24D9-455B-8E24-E965979F1656Q36698563-66DEA98E-48D2-49BA-B0A0-A3AC9BD30D0CQ37179405-D25DA424-75CE-48BC-8E30-BCA04E7A8487Q37203411-14ACCC56-0F8E-404D-96A8-35C9CAE3D3E0Q37824622-5450B4B3-1C18-4E31-B0F1-282B7774DE09Q37992481-A8E77C82-F5B8-4709-816F-FE39D5947994Q38149245-7366D2F4-615E-45B9-ACED-9B970BB25E26Q38623918-299CBCAE-D381-451F-A9FB-FE5DEC2E5B29Q42034570-6D2DBAEB-E3DB-4339-8372-4810B3913D55Q42267831-819FADE1-2531-402E-872D-8DBD074C5911Q42587971-B212D294-0DCC-4F35-81BD-6728F0223070Q43492270-3B6A4A93-25FE-41CD-88F7-549340EBFBE5Q43524369-F3A3D24F-253F-4389-AA02-24B06F4FD140Q50033803-6B97E8F1-750F-40E9-84A1-3C0E4A27EB9CQ53295389-CA31B331-233D-4550-9C7A-2A6807EB36E0Q57617318-552B1E96-F8B9-4EBE-AE49-550C3F8D5DC9
P2860
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@en
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@nl
type
label
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@en
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@nl
prefLabel
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@en
Promoter methylation and response to chemotherapy and radiation in esophageal cancer.
@nl
P2093
P1476
Promoter methylation and response to chemotherapy and radiation in esophageal cancer
@en
P2093
Austin Doyle
Bogdan Paun
Bruce D Greenwald
Carmit Mantzur
Fumiaki Sato
James P Hamilton
John M Abraham
Mark J Krasna
Martin J Edelman
Mohan Suntharalingam
P304
P356
10.1016/J.CGH.2006.03.007
P407
P50
P577
2006-05-04T00:00:00Z